Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US court refuses to block Sanofi-Aventis's insulin pen

This article was originally published in Scrip

Executive Summary

A US appeals court has affirmed a New Jersey judge's decision not to preliminarily enjoin sales of Sanofi-Aventis's Lantus (insulin glargine) SoloStar pre-filled disposable pen pending a decision on the merits of a patent dispute. Novo Nordiskalleged the SoloStar system infringed its patent on an insulin injection pen that requires less force to inject the medicine and prevents the user from dialing up a dose that exceeds the amount of insulin remaining in the pen. In February a New Jersey federal judge denied Novo Nordisk's request for a preliminary injunction, finding that the plaintiff failed to show a likelihood of success on the merits. The Federal Circuit Court of Appeals has now affirmed the ruling. The Lantus SoloStar pen entered the US market last year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts